BRCA mutation

January 14, 2020February 21, 2020

FDA Reviewing Lynparza-bevacizumab as First-line Maintenance for Advanced Ovarian Cancer, Regardless of BRCA Status

News

The U.S. Food and Drug Administration (FDA) has agreed to review AstraZeneca and Merck‘s request to extend the indication of oral Lynparza (olaparib) as a first-line maintenance therapy in combination with ... Read more

July 29, 2019

BRCA Testing for Ovarian Cancer Patients Could Be Decided by Family History and Age, Study Suggests

News

Women with ovarian cancer who have a family history of breast or ovarian cancer, and are younger than 45 if breast cancer in a near relative makes up that history, are ... Read more

October 24, 2018

Lynparza Maintenance Delays Progression in Ovarian Cancer Patients by 3 Years, Phase 3 Trial Shows

News

Ovarian cancer patients with BRCA mutations who received Lynparza (olaparib) maintenance treatment after first-line platinum-based chemotherapy lived three years longer without signs of disease worsening than patients who received a ... Read more

July 16, 2018

Lynparza Maintenance Delays Disease Progression in Advanced Ovarian Cancer, Phase 3 Trial Shows

News

Lynparza (olaparib), a PARP inhibitor, significantly prevents ovarian cancer from progressing or returning in women who responded to their first-line chemotherapy treatment, results from a Phase 3 trial show. The randomized, ... Read more

June 20, 2018

Zejula Added to UK’s Cancer Drugs Fund for Recurrent, Platinum-sensitive Ovarian Cancer

News

Women in England and Wales with recurrent, platinum-sensitive ovarian cancer can now access Zejula (niraparib) through the Cancer Drugs Fund (CDF) after a recommendation by the U.K.’s National Institute for Health and Care ... Read more

April 30, 2018

Zejula Shows Ability to Treat Range of Advanced Ovarian Cancers in Phase 2 Trial

News

Zejula (niraparib) showed an ability to treat people with recurrent and heavily treated ovarian cancer, particularly those with mutations in DNA repairing genes, results of a Phase 2 trial show. Tesaro’s ... Read more

January 6, 2017January 6, 2017

FDA Grants Accelerated Approval to Rubraca for BRCA-positive Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Clovis Oncology’s drug candidate Rubraca (rucaparib) to treat women with BRCA-positive advanced ovarian cancer, who have been treated with two or ... Read more